Love Home Swap is currently looking for participants to help them in a research project that will open the doors to better holiday options for people with accessibility needs.
World Brain Day 2021 is dedicated to multiple sclerosis (MS), a neurological disease that affects 2.8 million people of all ages globally. Disease-modifying treatments slow the progression of MS, yet access to these medications is unavailable in many parts of the world.
On World Brain Day, 22rd July the Neurological Alliance of Ireland (NAI) are launching their report on online service provision across neurological care services in response to COVID19. When the pandemic hit in 2020, many services moved online resulting in significant changes for both service users and service providers.
The MS International Federation is delighted to be partnering with the World Federation of Neurology (WFN) this year on World Brain Day. The 2021 theme is Stop Multiple Sclerosis.
As part of the 2021 World Brain Day campaign, the WFN and MSIF are inviting those with multiple sclerosis, their loved ones, healthcare professionals, multiple sclerosis organisations and everyone else to join in to raise awareness to stop multiple sclerosis through the use of the hashtag #WorldBrainDay2021.
MS Ireland would like to congratulate Prof. Alan Thompson on winning the 2021 Charcot Award. The Charcot Award recognises a lifetime achievement in outstanding research into understanding and treating MS. Prof. Thompson who is the Dean of the Faculty of Brain Sciences at UCL in the UK, is a long-time supporter of MS Ireland who has focused his 40-year career on the care and treatment of people living with MS.
To understand the opportunities and barriers for evaluating services delivered in MS Ireland.
Has your activity changed since the start of the pandemic?
The MHRA (Medicines and Healthcare products Regulatory Agency) and European Commission have granted marketing authorisation for an under-the-skin injection of Tysabri. Tysabri is a disease-modifying therapy for highly active relapsing-remitting MS.
UK experts are set to run a multi-arm, multi-stage trial which will test a range of drugs already approved for other illnesses for the treatment of multiple sclerosis (MS). The ‘Octopus trial’ will allow three drugs to be tested at the same time.
All-Ireland MS Research Network (AIMS-RN) provides hope to those affected by multiple sclerosis